LAUSR

Methotrexate and azathioprine had been administered to the patients with RA and MCTD, respectively. All 6 patients were histologically diagnosed as diffuse large B cell lymphoma. Because of the use of immunosuppressive drugs, 2 patients with RA and MCTD were classified as “other iatrogenic immunodeficiency-associated lymphoproliferative disorders” according to WHO classification (2008). The Ann Arbor clinical stages were II AE for 3 non-AD patients, and IV AE for 3 patients with ADs. According to the International Prognostic Index, all patients with ADs were classified as high risk. All patients received R-CHOP-like chemotherapy along with central nervous system (CNS) prophylaxis. Except for one patient who is receiving chemotherapy, all the patients achieved complete remission after the first chemotherapy regimen. Relapse was observed in two patients including one patient who experienced relapse in the CNS and the skin. Three patients have maintained complete remission at present, including one patient who is in the second complete remission for more than 8 years after salvage therapy for relapse. In cases with ADs, immunosuppressant was discontinued. There was no symptomatic worsening of ADs after chemotherapy.